Dexcom (DXCM) Capital Expenditures (2010 - 2026)

Dexcom (DXCM) has 17 years of Capital Expenditures data on file, last reported at $76.6 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $76.6 million, down 11.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $353.1 million (down 9.21% YoY), and the FY2025 annual result was $363.5 million, up 1.31% from the prior year.
• Capital Expenditures declined to $76.6 million in Q1 2026 per DXCM's latest filing, from $101.9 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $124.6 million in Q4 2024 and troughed at $50.4 million in Q3 2023.
• A 5-year average of $82.4 million and a median of $80.5 million in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 53.42% in 2023, then soared 137.33% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $63.5 million in 2022, then decreased by 17.32% to $52.5 million in 2023, then soared by 137.33% to $124.6 million in 2024, then fell by 18.22% to $101.9 million in 2025, then decreased by 24.83% to $76.6 million in 2026.
• Business Quant data shows DXCM's Capital Expenditures at $76.6 million in Q1 2026, $101.9 million in Q4 2025, and $80.5 million in Q3 2025.